2,3-二氢-N-甲基-1,4-苯并二氧杂环己-2-甲胺 | 2242-31-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 中文名称: 2,3-二氢-N-甲基-1,4-苯并二氧杂环己-2-甲胺
• 中文别名: (2,3-二氢-苯并[1,4]二氧杂芑-2-基甲基)-甲基-胺
• 英文名称: 2-(N-methylaminomethyl)-2,3-dihydro-1,4-benzodioxin
• 英文别名: 2-Methylaminomethyl-1,4-benzodioxan；(2,3-Dihydro-benzo[1,4]dioxin-2-ylmethyl)-methyl-amine；1-(2,3-dihydro-1,4-benzodioxin-3-yl)-N-methylmethanamine
• CAS: 2242-31-1
• 化学式: C₁₀H₁₃NO₂
• mdl: MFCD01659517
• 分子量: 179.219
• InChiKey: RPZMFKMYOVWSQN-UHFFFAOYSA-N

物化性质

• 沸点：
  124 °C(Press: 2 Torr)
• 密度：
  1.087±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2932999099

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-(2,3-Dihydro-1,4-benzodioxin-2-ylmethyl)-n-methylamine, HCl
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-(2,3-Dihydro-1,4-benzodioxin-2-ylmethyl)-n-methylamine, HCl
CAS number: 2242-31-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H13NO2.ClH
Molecular weight: 215.7

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,3-二氢-N-甲基-1,4-苯并二氧杂环己-2-甲胺 在 氨 、 三乙胺 作用下， 以 甲醇 、 乙醇 、 甲苯 为溶剂， 反应 2.0h， 生成 2,6-Dimethyl-4-(2-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-{2-[(2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-methyl-amino]-ethyl} ester 5-methyl ester
  参考文献：
  名称：

  New 1,4-dihydropyridine derivatives combining calcium antagonism and .alpha.-adrenolytic properties

  摘要：

  A series of twelve 1,4-dihydropyridine derivatives incorporating an alpha-adrenergic moiety in one of the ester chains was synthesized. The compounds were evaluated for their calcium antagonist activities by the inhibition of [3H]nitrendipine binding and, in vitro, on pig coronary artery. Their alpha 1- and alpha 2-adrenolytic effects were assessed from their inhibition of [3H]prazosin and [3H]yohimbine binding and, in vitro, on rat aorta and guinea pig vas deferens. Compounds 6 and 9-11 displayed strong calcium antagonist activities, identical with that of nicardipine. The moderate alpha-adrenolytic properties observed were attributed to the presence of alpha-adrenergic moieties. The four chiral derivatives 6a (R,R), 6b (S,S), 6c (S,R), and 6d (R,S) with an N-methyl-N-(benzodioxanylmethyl)amino group on the ester chain were prepared and tested as done previously. Some structure-activity relationships are discussed.

  DOI：

  10.1021/jm00126a042
• 作为产物：
  描述：

  1,4-苯并二氧六环-2-甲酸乙酯 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 水 、 甲苯 为溶剂， 反应 64.0h， 生成 2,3-二氢-N-甲基-1,4-苯并二氧杂环己-2-甲胺
  参考文献：
  名称：

  Design and synthesis of substituted compounds containing the 1,4-benzodioxin subunit. New potential calcium antagonists

  摘要：

  New compounds possessing 1,4-benzodioxin or its saturated analogous heterocyclic system were synthesized and tested for calcium antagonist activity. Biological differences were seen between the different modifications applied. These compounds have been shown to be representative of a novel series of calcium channel antagonists. (C) 2000 editions scientifiques et medicates Elsevier SAS.

  DOI：

  10.1016/s0223-5234(00)00164-1

文献信息

• [EN] SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS<br/>[FR] DÉRIVÉS DE SULFAMATE ET DE SULFAMIDE POUR LE TRAITEMENT DE L'ÉPILEPSIE ET DE TROUBLES APPARENTÉS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2006007435A1

  公开（公告）日：2006-01-19

  The present invention is directed to novel sulfamide and sulfamate derivatives, pharmaceutical composlons containing them and their use in the treatment of epilepsy and related disorders.

  本发明涉及新型磺胺酰胺和磺酸酯衍生物，包含它们的药物组合物以及它们在治疗癫痫和相关疾病中的用途。
• USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR LOWERING LIPIDS AND LOWERING BLOOD GLUCOSE LEVELS
  申请人：Smith-Swintosky L. Virginia

  公开号：US20070155821A1

  公开（公告）日：2007-07-05

  The present invention is a method for the glucose related disorders and lipid related disorders comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) or formula (II) as herein defined. The present invention is further directed to methods of treatment comprising co-therapy with an anti-diabetic agent, and anti-lipid agent and/or an anti-obesity agent.

  本发明涉及一种治疗葡萄糖相关疾病和脂质相关疾病的方法，包括向需要的受试者施用一种或多种新型苯并杂环磺胺衍生物的治疗有效量，其化学结构如公式(I)或公式(II)所定义。本发明还涉及治疗方法，包括与抗糖尿病药物、抗脂质药物和/或抗肥胖药物联合治疗。
• USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF DEPRESSION
  申请人：Smith-Swintosky L. Virginia

  公开号：US20070155827A1

  公开（公告）日：2007-07-05

  The present invention is a method for the treatment of depression comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as herein defined. The present invention is directed to a method for the treatment of depression, which includes mono-therapy and alternatively, co-therapy with at least one antidepressant.

  本发明涉及一种治疗抑郁症的方法，包括向需要的受试者施用一种或多种新型苯并杂环磺酰胺衍生物的治疗有效量，其化学式为(I)和(II)。本发明涉及一种治疗抑郁症的方法，包括单独治疗和/或与至少一种抗抑郁药物联合治疗。
• Synthesis and pharmacological properties of soft drug derivatives related to perhexiline
  作者：Gilbert Marciniak、Dominique Decolin、Gerard Leclerc、Nicole Decker、Jean Schwartz

  DOI：10.1021/jm00120a007

  日期：1988.12

  cyclohexylaralkylamines II based on the "soft drug" concept and incorporating an amide function were synthesized. In a preliminary screening, compounds were evaluated for their alpha-adrenolytic activities. Several derivatives, especially N-(cyclohexylphenylmethyl)-2-(cyclohexyl-methylamino)acetamide (3), N-(cyclohexylphenylmethyl)-2-(homoveratrylmethylamino)acetam ide (7), and N-[2-(cyclohexylamino)ethyl]-alpha-

  为了减少哌克昔林的毒性，合成了一系列基于“软药物”概念并结合酰胺功能的27种环己基烷基胺II。在初步筛选中，对化合物的α-肾上腺素分解活性进行了评估。几种衍生物，尤其是N-（环己基苯基甲基）-2-（环己基甲基氨基）乙酰胺（3），N-（环己基苯基甲基）-2-（全过甲基甲基氨基）乙酰胺（7）和N- [2-（环己基氨基）乙基] -α-环己基苯乙酰胺（23）在大鼠主动脉条中的体外活性范围与哌己昔林相同。然后研究了这三种分子的体外代谢，并将其与哌己昔林进行了比较。研究了在II上引入各种N-芳烷基胺基对α-肾上腺素解活性的影响。
• USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN
  申请人：Smith-Swintosky L. Virginia

  公开号：US20070155822A1

  公开（公告）日：2007-07-05

  The present invention is a method for the treatment of pain comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as described herein. The present invention is further directed to methods for the treatment of pain comprising co-therapy with analgesic agent(s) and a compound of formula (I) or formula (II) as described herein.

  本发明涉及一种用于治疗疼痛的方法，包括向需要的受试者施用一种或多种根据本文描述的新型苯并杂环磺酰胺衍生物的治疗有效量。本发明还涉及一种治疗疼痛的方法，包括与镇痛剂联合治疗，并根据本文描述的化合物的公式(I)或公式(II)。